Xenetic Biosciences XBIO
NASDAQ XBIO
$2.24 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Xenetic Biosciences (XBIO) Asset Writedowns and Impairment (2020)

Updated

Xenetic Biosciences' Asset Writedowns and Impairment came in at $9.24 million for FY2020, up 181.5% from $3.28 million in FY2019.

Analysis

Xenetic Biosciences (XBIO) Asset Writedowns and Impairment (2020) Analysis & Trends

  • Per Business Quant, earlier years put Asset Writedowns and Impairment at $3.28 million in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Xenetic Biosciences 5.25 Mn -20.58 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 9.24 Mn
API Access

Xenetic Biosciences Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=XBIO&period=max&api_key=YOUR_API_KEY